Abstract:In pediatric age and particularly in newborn infants the drug efficacy and safety are influenced by the growth and development on drug Absorption, Distribution, Metabolism and Excretion (ADME). Thanks to the fast development of pharmacogenomics and pharmacogenetics, the drug therapy promises to be adapted to the genetic profile of the individual, reducing considerably the side effects of drugs and increasing their efficacy. Interindividual variability in drug response is well known in both adults and children. Such a variability is multifactorial considering both intrinsic and extrinsic factors. Drug distribution in the neonate is influenced by a variety of age-dependent factors as a total body water content and distribution variations, role of drug transporters, blood/tissue protein binding, blood and tissue pH and perfusion. The development of enzymes involved in human metabolism were classified in 3 categories: 1) those expressed during the whole or part of the fetal period, but silenced or expressed at low levels within 1-2 years after birth; 2) those expressed at relatively constant levels throughout fetal development, but increased to some extent postnatally; and 3) those whose onset of expression can occur in the third trimester, but substantial increase is noted in the first 1-2 years after birth. Besides this intrinsic aspects influencing pharmacokinetics during the neonatal period there are other important events such as inborn or acquired diseases, environment and finally pharmacogenetics and pharmacogenomics. Thousands of deaths every years are caused by fatal drug reactions; among the potential causes there are not only the severity of the disease being treated, drug interactions, nutritional status, renal and liver functions, but also the inherited differences in drug metabolism and genetic polymorphism. Adverse drug reactions (ADRs) among pediatric patients have been shown to be three times more frequent than in adults. On August 2010 The National Institute of Child Health and Human Development (NICHD) addressed patient safety issues in the NICU, recognizing that to understand and prevent adverse events, systematic research and education in safety issues needed. From all these concepts in terms of ADME, pharmacogenetics (relative to a single gene) and pharmacogenomics (relative to many genes) it is becoming more evident the perspective of the new concept of individualized medicine. The goal of this should be to identify which group of patients responds positively, which patients are nonresponders and who experiences adverse reaction for the same drug and dose. The interindividual variability in response to any drug is mostly dependent on DNA sequence variations across the human genome, the haplotype map (HAPMAP). At present there is still a big distance beween the knowledge in genetic and the practical application to model the drug profile to the genetic/genomic profile of the single patient. In the neonatal period the effects of growth in the pharmacodynamic, processes can help optimizing the dosage of neonatal frequently used medicines, thereby, minimizing their toxicity and increasing their efficacy. It should be useful to create accurate dosage adjustments according to the week of development.

Applied pharmacokinetics to improve pharmacotherapy in neonatal and paediatric intensive care units: focus on correct dose selection

Dosage individualization in children: integration of pharmacometrics in clinical practice

Pharmacometric in silico studies used to facilitate a national dose standardisation process in neonatology – application to amikacin

Principles and Applications of Pharmacometrics in Drug Evaluation in Children.

Neonatal Clinical Pharmacology

Ontogeny and drug metabolism in newborns

Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program

Therapeutic drug monitoring in neonates

Variation in vancomycin dosing and therapeutic drug monitoring practices in neonatal intensive care units

Optimisation of Vancomycin Exposure in Neonates Based on the Best Level of Evidence.

[Dosing regimens of antibiotics in neonates: Variations in clinical practice and what should be done?].

Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing

Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates

Vancomycin Continuous Infusion in Neonates: Dosing Optimisation and Therapeutic Drug Monitoring

Ethics of Drug Research in the Pediatric Intensive Care Unit

Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment

Developmental Changes in Pharmacokinetics and Pharmacodynamics

Pharmacokinetic model‐guided enoxaparin dosing in the Neonatal ICU: Retrospective cohort study to plan for prospective feasibility trial

Physiologically-based pharmacokinetic modeling and dosing optimization of cefotaxime in preterm and term neonates

Drug dosing optimization in critically ill children under continuous renal replacement therapy: from basic concepts to the bedside model informed precision dosing

Dose optimization and target attainment of vancomycin in children